Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Randox Laboratories has introduced an automated laboratory assay for Heart-type Fatty Acid Binding Protein (H-FABP) for use in combination with Troponin in the diagnosis and management of suspected acute coronary syndrome (ACS).
Subscribe to our email newsletter
H-FABP, which is a low-weight cytoplasmic protein (15kDa), demonstrated high sensitivity.
Study from the University of Manchester, UK, suggested that using a combination hsTnT, H-FABP and ECG on admission, could act as a highly accurate rule-out test for AMI.
Two recent landmark studies from a group based at Leeds General Infirmary, UK, showed that H-FABP offers independent and additive prognostic value across the full spectrum of ACS patients, and is a significant predictor of mortality in both Troponin positive and negative patients.
The Troponin negative patients are of particular importance, as this group are usually stratified as low-risk and frequently may be discharged from hospital.